Thursday, 25 June Table 1, Karen Adelman, PhD
National Institute of Environmental Health Sciences, United States
Website: http://www.niehs.nih.gov/research/atniehs/labs/escbl/pi/tre/ Expertise: Table 2, Robin Ali, PhD, FMedSci
The Adelman laboratory is interested in the regulation of gene expression and chromatin structure in response to specific environmental and developmental signals. By elucidating the fundamental molecular basis for transcriptional responses to extracellular cues, we aim to provide insights into gene-environment interactions during the maintenance of homeostasis and reaction to injury, as well as during development.
University College London, United Kingdom
Website: http://www.kellogg.umich.edu/bios/ali.research.html Expertise: Table 3, Kari K. Alitalo, MD, PhD
The main focus of our laboratory is the development and validation of novel gene and stem cell therapies for eye disease. Specifically, we focus on disorders affecting the retina, including inherited retinal degeneration and diseases associated with retinal and choroidal neovascularisation and posterior uveitis. Dr. Ali and his group have published multiple seminal papers that demonstrated the feasibility, safety and effectiveness of gene therapy to treat retinal diseases.
University of Helsinki, Molecular and Cancer Biology Lab, Finland
Website: http://research.med.helsinki.fi/cancerbio/alitalo/Index.html Expertise: Table 4, Nathalie Le Bot, PhD Nature, United Kingdom
Our objective is the discovery and characterization of novel growth factor-receptor signaling network interactions, and their use in the design of effective anti-angiogenic treatments for cancer. In particular, we want to explore the relationship of cancer stem cells, tumor vasculature and angiogenesis. As a convenient model, we use transgenic mice and cancer stem-cell based organoid cultures from colorectal cancer patients.
Website: http://www.nature.com/nature/about/editors/ Expertise: Table 5, Chad Cowan, PhD, HSCRB
Nathalie Le Bot is the stem cell and development editor at Nature. Dr. Le Bot joined the Nature editorial team in August 2014, after eight years as an editor at Nature Cell Biology, where she also had responsibility for papers in the field of developmental biology.
Harvard University, United States
Website: http://www.scrb.harvard.edu/lab/43/home Expertise: Table 6, Allen Eaves, MD, PhD, FRCPC
The Cowan Lab's goal is to understand the molecular underpinnings of metabolic diseases such as type 2 diabetes mellitus and coronary artery disease and use these insights to develop new therapies. We use human cell-based models to understand how DNA variants affect gene and protein function or how lifestyle choices such as exercise and diet influence disease progression and then use these mechanistic insights to begin the process of developing new therapies that will benefit patients and populations. We use genome editing tools to generate specific DNA variants in human pluripotent stem cells which when differentiated into human-derived tissues provide genetic disease models. We also aim to use stem cells to enable regenerative medicine, in which a patient’s own cells can be genetically cured or made resistant to disease and then transplanted back into the body as a durable treatment.
STEMCELL Technologies Inc, Canada
Website: http://www.stemcell.com/ Expertise: Table 7, Kevin C. Eggan, PhD
Dr. Allen Eaves is the Founder, President and CEO of STEMCELL Technologies Inc., a global biotechnology company which develops and markets specialty cell culture media, cell separation products, reagents and instruments required for life science research. He was previously Professor and Head of Clinical Hematology at University of British Columbia and was the co-founder and Director of the Terry Fox Laboratory for Hematology/Oncology Research.
Harvard University, United States
Website: http://www.scrb.harvard.edu/lab/44/home Expertise: Table 8, Amanda Fisher, PhD, FRS
We have committed our research program to determining the mechanisms that cause motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and seek to translate our discoveries into new therapeutic options for patients. In order to achieve these goals, we operate at the interface between the fields of stem cell biology, genetics, developmental neuroscience and the neurobiology of disease. We have also now begun to expand our interests, applying similar strategies to the study of psychiatric conditions.
Imperial College London, United Kingdom Table 9, Fred H. Gage, PhD
Salk Institute for Biological Studies, USA
Website: http://www.salk.edu/faculty/gage.html Expertise: Table 10, Stephen Huhn, MD StemCells, Inc., United States
Fred H. Gage, a professor in the Laboratory of Genetics, concentrates on the adult central nervous system and unexpected plasticity and adaptability to environmental stimulation that remains throughout the life of all mammals.
Website: http://www.stemcellsinc.com/About-Us/People/Leadership-Team.htm Expertise: Table 11, Jürgen Knoblich, PhD IMBA-Institute of Molecular Biotechnology, Austria
Dr. Huhn is the Vice President, CNS Clinical Research and Chief Medical Officer of StemCells, Previously, Dr. Huhn directed the preclinical and clinical development programs for CNS indications. Prior to joining StemCells, Inc he was an Associate Professor of Neurosurgery at Stanford University and Chief of Pediatric Neurosurgery at the Lucile Salter Packard Children's Hospital. Dr. Huhn maintains a Consulting Associate Professor appointment with the Department of Neurosurgery at Stanford University.
Expertise: Table 12, Michael May, PhD Centre for Commercialization of Regenerative Medicine (CCRM), USA
The Knoblich lab studies neural stem cells and brain development in fruit flies and in mammals. We have developed a three dimensional culture method to recapitulate the early development of a human brain in culture starting from ES or iPS cells and uses this method to analyze human brain diseases.
http://ccrm.ca/ Expertise: Table 13, Cristina Lo Celso, PhD Imperial College London, United Kingdom
Michael May is President and Chief Executive Officer of CCRM, a Canadian not-for-profit organization supporting the development of foundational technologies that accelerate the commercialization of stem cell-and biomaterials-based products and therapies.
Website: http://www.imperial.ac.uk/people/c.lo-celso Expertise: Table 14, Charles Murry, MD, PhD United States
Cristina Lo Celso's research focuses on understanding the cellular and molecular processes that regulate somatic stem cell function, specifically haematopoietic stem cells, and in particular how extrinsic systemic and local signals guide stem cell fate. Intravital microscopy guides my observations and I use an interdisciplinary approach combining advanced microscopy, computational analysis, molecular profiling, in vivo assays and mathematical modelling. I endeavour to apply the acquired knowledge to develop interventions that will 'manage' the haematopoietic system in order to improve current therapies and prevent disease.
Website: http://www.pathology.washington.edu/research/labs/murry/ Expertise: Table 15, Hiromitsu Nakauchi, MD, PhD University of Tokyo, Japan Table 16, Duanqing Pei, PhD Guangzhou Institute of Biomedicine & Health CAS, China
Chuck Murry is a cardiovascular pathologist whose research focuses on cardiovascular applications of stem cell biology, with an emphasis on human pluripotent stem cells. He studies the molecular basis for cardiovascular differentiation, modeling of cardiomyopathies using hiPSCs, and strategies for heart regeneration using cell therapy and tissue engineering.
Website: http://english.gibh.cas.cn/home/mt/qing/ Expertise: Table 17, Carla Kim, PhD
The Pei lab explores new ways to improve iPS technology, dissect the reprogramming mechanisms driven by Oct4/Sox2/Klf4 or fewer factors, and employs iPSCs to model human diseases in vitro.
Children's Hospital Stem Cell Program, United States
Website: http://kim.tchlab.org/">http://kim.tchlab.org/ Expertise: Table 18, András Simon, PhD Karolinska Institutet, Sweden
The broad interest of the Kim Lab is to characterize the biology of stem cells in normal lung and lung cancer. Our long-term goal is to elucidate the role of stem cells in lung homeostasis as a prerequisite to the development of therapeutic strategies that can be used to prevent or attenuate lung disease.
Website: http://ki.se/en/cmb/andras-simons-group Expertise: Table 19, Deborah Sweet, PhD Cell Press, USA
Our group has two main interests. 1) To reveal how adult neurogenesis and brain regeneration takes place. Here we focus on the role of neurotransmitter signaling in neurogenesis during normal physiological conditions and also after neuronal ablation. 2) To understand how skeletal muscle contributes to new tissues during limb regeneration. We have identified a Pax7+ stem cell population in salamander skeletal muscle and we try to understand how these cells take part in limb regeneration.
Website: http://www.cell.com/about Expertise: Table 20, Sowmya Viswanathan, PhD University Health Network, Princess Margaret Hospital, Canada
Debbie Sweet leads the Cell Press editorial team across a broad range of organizational and business development areas, and editorial perspective for the overall strategic development of Cell Press. She maintains strategic and operational management of a group of journals comprising 6 primary research journals and 2 Trends review journals and is the launch and current Editor of Cell Stem Cell
, responsible for scientific and strategic leadership of the journal and the editorial team.
Website: http://www.ibbme.utoronto.ca/faculty/cross-appointed-faculty-2/ Table 21, Juan Carlos Zúñiga-Pflücker, PhD Department of Immunology University of Toronto, Canada
Dr. Viswanathan is a translational scientist at the Toronto Western Research Institute, University Health Network, and an Assistant Professor at the Institute of Biomaterials and Biomedical Engineering, University of Toronto. Her research interest is focused on understanding the biology of mesenchymal stromal cells (MSCs) in modulating inflammatory responses in the context of osteoarthritis (OA), and translating these findings into clinical investigations.
Website: http://www.immunology.utoronto.ca/faculty/directory/zunigapflucker.htm Expertise: Table 22, Masayo Takahashi, MD, PhD RIKEN Center for Developmental Biology Kobe Institute, Japan
Our laboratory is generally interested in the molecular control of hematopoiesis, lymphocyte lineage commitment and T cell development. Specifically, we have three goals: 1) understanding the early events that multi-potent precursor cells experience as they enter the thymus, 2) the identification of the molecular events that are induced following the formation of the pre-T cell receptor complex and 3) to develop an in vitro system for the differentiation of embryonic stem (ES) cells into functional lymphocytes, B, NK, and T cells.
Website: http://www.cdb.riken.jp/en/research/laboratory/takahashi.html Expertise:
Our research into retinal regeneration seeks to achieve clinical applications by developing methods for inducing stem cells or embryonic stem cells to differentiate into retinal neurons and pigment epithelial cells in sufficient quantities for use in the treatment of patients suffering from conditions in which such cells have been damaged or lost.